Raphael Pharmaceutical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2019
Net Income	-1.28	-1.52	-1.34	-3.36	-1.62	Upgrade
Stock-Based Compensation	0.25	0.39	0.2	2.29	-	Upgrade
Change in Accounts Payable	0.01	0.41	-0.13	0.1	0.23	Upgrade
Change in Other Net Operating Assets	0.82	0.19	0.07	0.21	-0.03	Upgrade
Operating Cash Flow	-0.21	-0.53	-1.2	-0.76	-1.42	Upgrade
Capital Expenditures	-	-	-	-0	-	Upgrade
Investing Cash Flow	-	-	-	-0	-	Upgrade
Short-Term Debt Issued	-	0.04	-	-	0.17	Upgrade
Total Debt Issued	-	0.04	-	-	0.17	Upgrade
Short-Term Debt Repaid	-0.01	-	-	-	-	Upgrade
Total Debt Repaid	-0.01	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	-0.01	0.04	-	-	0.17	Upgrade
Issuance of Common Stock	0.24	0.28	1.15	0.9	1.29	Upgrade
Other Financing Activities	-	-	-	-	0.01	Upgrade
Financing Cash Flow	0.24	0.32	1.15	0.9	1.48	Upgrade
Net Cash Flow	0.03	-0.21	-0.06	0.14	0.06	Upgrade
Free Cash Flow	-0.21	-0.53	-1.2	-0.76	-1.42	Upgrade
Free Cash Flow Per Share	-0.01	-0.03	-0.07	-0.05	-0.13	Upgrade
Levered Free Cash Flow	0.18	0.04	-0.69	0.37	-0.77	Upgrade
Unlevered Free Cash Flow	0.19	0.04	-0.69	0.37	-0.77	Upgrade
Change in Working Capital	0.82	0.6	-0.06	0.31	0.21	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.